Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial
Background Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response. Objective To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment reintroduction after flare in adolescent and adult...
Saved in:
Main Authors: | Carsten Flohr (Author), Michael J. Cork (Author), Michael R. Ardern-Jones (Author), Lawrence F. Eichenfield (Author), Sébastien Barbarot (Author), Claire Feeney (Author), Ricardo Rojo (Author), Irina Lazariciu (Author), John Nesnas (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: A post hoc analysis of the JADE clinical trials
by: Melinda J. Gooderham, et al.
Published: (2023) -
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
by: Melinda J. Gooderham, MSc, MD, FRCPC, et al.
Published: (2021) -
Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations
by: Melinda J. Gooderham, et al.
Published: (2024) -
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
by: Helena Iznardo, et al.
Published: (2023) -
Abrocitinib: A Comprehensive Review of its Efficacy and Safety in Dermatology
by: Sunil Dogra, et al.
Published: (2024)